Sanofi bets $425M cash on a transformation-style next-gen vaccine deal — as the Big Pharma team makes a point

Back at the end of last March, with the world locking down in the face of a pandemic, Sanofi tied up with mRNA biotech …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi bets $425M cash on a trans­for­ma­tion-style next-gen vac­cine deal — as the Big Phar­ma team makes a point